Abbott Laboratories' shares rose 2.37% after reporting strong Q2 results and raising its 2026 earnings guidance, driven by growth in diagnostics, devices, and strategic acquisitions.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.